Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

Returns vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

#CNBCAwaazLive #BusinessNewsLive #StockMarket #ShareMarketToday 

Natco Pharma पर Manas Jaiswal से लें सलाह, Stock Bottom बनाने की कोशिश कर रहा है, हालांकि इस Stock में Breakout का इंतजार है 807 रुपये के ऊपर खरीदारी की राय दी जा रही है। देखें वीडियो

Share Market से जुड़ी हर छोटी या बड़ी खबर, चाहे हो Nifty में आए नए हाई या फिर, हो आपके के लिए स्टॉक्स पर राय, बिजनेस न्यूज हो या पॉलिटिकल न्यूज, कोरोनावायरस की न्यूज हो या फिर इलेक्शन, देखें CNBC Awaaz और रहे हर खबर से updated.


CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz

NATCO PHARMA पर Manas Jaiswal से खरीदारी पर लें सलाह | Pehla Sauda | CNBC Awaaz

Natco Pharma on Thursday announced that it has launched a tablet for the treatment of advanced colorectal and gastric cancer in India.

Natco Pharma launches gastric cancer tablet in India

Natco Pharma has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country. The company has launched the product under the brand name Tipanat in a pack of 20 tablets in a bottle

Natco Pharma launches novel fixed-dose combination drug for colorectal, gastric cancer

Natco Pharma on Thursday said it has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country.

Natco Pharma launches novel drug for colorectal, gastric cancer

The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application.

NATCO Pharma announces launch of Everolimus Tablets in U.S. market

Tipanat is a novel antineoplastic nucleoside analog indicated for the treatment of advanced colorectal and gastric cancer.

Natco Pharma launches cancer drug - Tipanat in India

NATCO Pharma launches Tipanat tablets for advanced colorectal, gastric cancer treatment in India

The firms whose applications that will be taken up are Dr Reddy’s Laboratories which has filed for approval in a consortium with five other companies and MSD, Hetero Labs, Natco Pharma, Aurobindo Pharma, Optimus Pharma, Strides Pharma, MSN Pharma and BDR Pharmaceuticals.

Panel to meet today to take up applications seeking nod for Molnupiravir

Natco Pharma fell 2.09% to Rs 805.70 after the company’s consolidated net profit tumbled 68.1% to Rs 65.10 crore on a 53% drop in net sales to Rs 377.20 crore in Q2 September 2021 over Q2 September 2020.

Natco Pharma declines after Q2 FY22 PAT skids 68% to Rs 65 cr

Drugmaker Natco Pharma reported consolidated net profit declined more than 68% to ₹65.1 crore for the September quarter. The lower profit, compared with ₹203.90 crore in the year-earlier period, came

Natco Pharma profit slumps 68% to ₹65 cr.

The Hyderabad-based firm had posted a consolidated net profit of Rs 203.9 crore in the July-September quarter of the previous fiscal.

Natco Pharma Q2 Net Profit Drops 68% To Rs 65 Crore

Natco Pharma Limited is a research and development (R&D)-focused pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).

Natco Pharma Ltd

Natco Pharma Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

NATCO PHARMA पर Manas Jaiswal से खरीदारी पर लें सलाह | Pehla Sauda | CNBC Awaaz

Natco Pharma launches gastric cancer tablet in India

Natco Pharma launches novel fixed-dose combination drug for colorectal, gastric cancer

Natco Pharma launches novel drug for colorectal, gastric cancer

NATCO Pharma announces launch of Everolimus Tablets in U.S. market

Natco Pharma launches cancer drug - Tipanat in India

NATCO Pharma launches Tipanat tablets for advanced colorectal, gastric cancer treatment in India

Panel to meet today to take up applications seeking nod for Molnupiravir

Natco Pharma Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

NATCO PHARMA पर Manas Jaiswal से खरीदारी पर लें सलाह | Pehla Sauda | CNBC Awaaz

Natco Pharma launches gastric cancer tablet in India

Natco Pharma launches novel fixed-dose combination drug for colorectal, gastric cancer

Natco Pharma launches novel drug for colorectal, gastric cancer

NATCO Pharma announces launch of Everolimus Tablets in U.S. market

Natco Pharma launches cancer drug - Tipanat in India

NATCO Pharma launches Tipanat tablets for advanced colorectal, gastric cancer treatment in India

Panel to meet today to take up applications seeking nod for Molnupiravir

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock